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Edited by Lukas HuberAbstract The proto-oncogene c-Myc is involved in early neo-
plastic transformations. Two consensus Lef/Tcf binding elements
(TBE) were found to be prerequisite for transcriptional transac-
tivation by the armadillo proteins b-catenin and plakoglobin
(PG) together with Tcf4 in human neoplastic cells. In epidermal
keratinocytes, c-Myc was reported to be repressed by Lef-1 and
PG. Using reporter gene assays, here we demonstrate that dele-
tion of the two consensus TBE fails to abrogate transcriptional
regulation by Lef-1/PG in wildtype and b-catenin/ keratino-
cytes, while it reduces transcription in pre-neoplastic PG/
keratinocytes. We identiﬁed a TBE sequence variant down-
stream of the major transcriptional initiation site that binds
Lef-1 in vitro and in vivo, and its mutation compromised tran-
scriptional regulation by Lef-1/PG. Collectively, this study dem-
onstrates that the two consensus TBE’s reported in neoplastic
cells are dispensable for c-Myc regulation in normal keratino-
cytes, which instead use a novel TBE sequence variant. This
unprecedented ﬁnding may have important implications for
armadillo target genes involved in carcinogenesis.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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We recently reported that suppression of the proto-oncogene
c-Myc is crucial for mouse keratinocytes to exit the cell cycle
and proceed to terminal diﬀerentiation [1,2]. Using chromatin
immunoprecipitation we further showed that this occurs by
recruitment of the transcription factor Lymphoid enhancer-
binding factor-1 (Lef-1) and the armadillo protein plakoglobin
(PG) to the c-Myc promoter at cell cycle exit when both PG
and Lef-1 are expressed in cultured keratinocytes or in epider-
mis [2,3].
Lef-1 is a member of the family of high-mobility group
(HMG) proteins with crucial functions in embryonic develop-Abbreviations: PG, plakoglobin; TBE, Lef/Tcf binding element; Oligo,
oligonucleotide; HMG, high mobility group
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to bind to Tcf/Lef binding elements (TBE) with the speciﬁc
nucleotide sequence 5 0- (A/T)(A/T)CAAAG-3 0 [6–8] or 5 0-(A/
T)(A/T)CANAG-3 0 [8]. In association with b-catenin and on
some occasions also with PG, Lef-1 mostly confers transcrip-
tional activation [9]. Some rare reports also demonstrated that
Lef-1 together with b-catenin or PG can exert negative tran-
scriptional regulation like suppression of E-cadherin in the
developing hair follicle, of c-Myc at the onset of terminal dif-
ferentiation in epidermal keratinocytes or of the mouse matrix
metalloproteinase-7 promoter [2,10,11]. In the latter, a TBE
downstream of the transcription start site was found to medi-
ate transcriptional repression via Lef-1 [10].
C-Myc is a proto-oncogene which is upregulated in most hu-
man cancers and its expression shows a negative correlation
with the patient’s prognosis [12]. Hence, transcriptional activa-
tion of c-Myc remains the subject of extensive investigations,
and has been found to be tightly controlled by a variety of
transcription factors. As Wnt signaling and b-catenin are cen-
trally involved in cancerogenesis in many tissues such as intes-
tine, colon and hair follicle in skin, the transcriptional
regulation of c-Myc by b-catenin was one of the ﬁrst areas
of investigation following the discovery that b-catenin is an
eﬀector of the Wnt pathway [13–15].
In colon cancer cell lines and during oncogenic transforma-
tion of kidney epithelial cells, two TBE of relevance for b-cate-
nin- or PG-mediated transcriptional activation were identiﬁed
in the human c-Myc promoter [16,17]. The ﬁrst site (TBE1) is lo-
cated 1198 bp and the second (TBE2) 626 bp upstream of the
major transcription initiation site (P2). In colon cancer cell lines
transcriptional activationwas suggested to occur in cooperation
with the Lef/Tcf family member Tcf4 [16]. The work on kidney
epithelial cells stipulated that PG is a more eﬀective transcrip-
tional transactivator of c-Myc than b-catenin during neoplastic
transformation [17]. The latter is underscored by the ﬁnding that
PG and not b-catenin drives c-Myc expression in acute myeloid
leukemia [18]. Consistently, Lef-1-mediated c-Myc repression at
the transition between proliferation and onset of terminal diﬀer-
entiation in epidermal mouse keratinocytes also occurred via
PG but not b-catenin [2]. The latter is consistent with the ﬁnding
that b-catenin is dispensable for onset of terminal diﬀerentiation
in epidermal keratinocytes [3] while PG is not [2].
During the course of our studies on c-Myc transcriptional
regulation [2], we observed that deletion of the two consensus
TBE failed to abrogate Lef-1 and PG-mediated transcriptional
regulation of a human c-Myc promoter-driven reporter gene.
This suggested that Lef-1 in association with PG uses otherblished by Elsevier B.V. All rights reserved.
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keratinocytes than reported so far. Here we set out to deﬁne
these binding sites by analyzing deletions and point mutations
of the c-Myc promoter sequence in reporter gene assays. To
discriminate between the activity of PG and b-catenin, the pro-
moter constructs were mainly analyzed in mouse wild-type, b-
catenin/ and PG/ keratinocytes as well as in primary
human keratinocytes (HK). In combination with band shift
experiments and chromatin immunoprecipitation (ChIP) the
current study identiﬁes a new TBE that is used for c-Myc sup-
pression in vitro and in vivo, lies distal to the transcriptional
initiation site and has a variant TBE sequence, which to the
best of our knowledge has not been reported to date.2. Materials and methods
2.1. Keratinocyte cultures
The isolation, characterization and cultivation of mouse wild-type,
b-catenin/ and PG/ keratinocytes (all C57BL6 genetic back-
ground) was described previously [2,3,19]. Primary human keratino-
cytes from foreskin (HK) were grown in CnT-07 (0.07 mM calcium;
cells and medium were from CELLnTEC, Bern, Switzerland).
2.2. Plasmids
Human Lef-1, DLef-1 and PG (all kind gifts of R Kemler, Freiburg,
Germany) and deletion mutants of PG (kind gift of A. Ben-Ze’ev,
Rehovot, Israel) were described previously [20,21]. Reporter gene con-
struct Del 2 (called here wild-type) or Del 4 (called here DTBE1/2) are
in a Pbv-Luc vector (kind gifts of E. Fearon, Ann Arbor, MI) [17,16].
In the construct called here ‘‘empty vector’’ the entire c-Myc promoter
was excised. Mutations in the TBE3 (5 0-CCCAAAG-3 0) and TBE4 (5 0-
CTTTGCA-3 0) were introduced following the protocol for ‘‘Quick-
ChangeII-E Site-Directed Mutagenesis’’ Kit (Stratagene, La Jolla,
CA). Brieﬂy the mutated plasmids were ampliﬁed by Pvu Polymerase
using primers (Microsynth, Balgach, Switzerland) designed with mis-
matches at the TBE (5 0-GCCCCCG-3 0 for MutTBE3 and 5 0-
CGGGGGC-3 0 for MutTBE4). Template vectors were digested with
DpnI (digesting methylated DNA) and engineered plasmids transfec-
ted into XL-1 blue cells for ampliﬁcation and sequencing.
2.3. Reporter gene assay
The assay was performed using the DualLuciferaseReporter Assay
System (Promega, Wallisellen, Switzerland). One day after seeding,
wild-type, b-catenin/, PG/ mouse keratinocytes or HaCaT cells
were transfected with 1.25 lg of reporter gene constructs and 0.8 lg
plasmid DNA encoding various factors or the vector alone (pc52) as de-
scribed previously [2]. Experiments were run in duplicates (except in
Fig. 1F) two to ﬁve times. Reporter gene assay values are shown as ratio
of ﬁreﬂy over renilla Luciferase used as normalizer. For each value
basal activity induced by the vector pc52 alone (shown in Fig. 1B,E
(control)) was subtracted. Statistical signiﬁcance (P < 0.05) was
assessed by the Kruskal–Wallis test for comparisons of two groups.
2.4. Electrophoretic mobility shift assay
Oligonucleotides (oligos) contained the consensus TBE2 of the
human c-Myc promoter (5 0-GCGGGCGGGCACTTTGATCTGGA-
ACTTACA-30), the variant TBE4 (5 0-GCGGGCGGGCACTTTG-
CACTGGAACTTACA-3 0) or a mutant oligo (5 0-GCGGGCGG-
GCACGGGGATCTGGAACTTACA-3 0); the ﬂanking sequences,
corresponding to TBE4, were kept constant. Oligos were labeled with
phosphoramidite Dye IRD700 or 800 (Metabion, Martinsried, Ger-
many) and used as recommended by LI-COR (LI-COR Biosciences,
Lincoln, NE) at a ﬁnal concentration of 0.2 or 1.0 pmol/ll (5·). Alter-
natively 0.5 and 2.5 pmol/ll were also found to give good results. For
competition a non-labeled TBE2 oligo (Microsynth, Balgach, Switzer-
land) was used at 40 pmol/ll (200· excess as recommended by Li-
COR). Each reaction contained 75 mM NaCl, 20 mM HEPES,
1 mM DTT, 2 mM MgCl2, 5% Glycerin and 40 ng poly(dI/dC; for
Lef-1/oligo binding reactions, 150 ng recombinant Lef-1 protein wasused (kind gift from R. Grosshedl, Max-Planck Institute, Freiburg
Br., Germany [22]). Reactions were incubated 20 min at RT in the
dark, loaded onto a 4% non-denaturing, non-reducing polyacrylamide
gel and run at 4 in a 25 mM Tris, 190 mM Glycin buﬀer for 90 min at
180 V. Gels were imaged and quantiﬁed using the double laser instru-
ment from LI-COR (Odyssey infrared imaging system).
2.5. Chromatin immunoprecipitation (ChIP)
The assay including culture and stimulation conditions was as de-
scribed [2], with the following exceptions: primary human keratino-
cytes from foreskin were grown until conﬂuency, 1.2 mM CaCl2 was
added to the medium and cells harvested two and four days later.
The sonication time was expanded to obtain fragments between 300
and 500 bp and discriminate between TBE1 and TBE2. The immuno-
precipitations were done with a polyclonal goat Lef-1 antibody and a
polyclonal goat IgG control (both Santa Cruz Biotechnology). Precip-
itated DNA was assessed by quantitative PCR using primers covering
or directly adjacent to TBE1 (B), TBE2 (C), TBE4 (D) and a negative
control sequence 1 kb upstream of TBE1 (A) (Fig. 2B and supplemen-
tal Table). Primers were designed and validated as described previously
[1]. Samples were corrected for input DNA and values obtained were
normalized versus the IgG control. The assay was done once.3. Results
3.1. Deletion of TBE1/2 does not abrogate c-Myc promoter
activity in keratinocytes
Our results on Lef-1/PG-mediated c-Myc suppression [2] were
reproduced in this study by reporter gene assays using a human
c-Myc promoter-driven luciferase reporter gene (Fig. 1A and
supplemental data 1) [17,16]. Ectopic expression of human
Lef-1 activated transcription from the wild-type promoter by
10-fold above background, while PG suppressed the Lef-1-med-
iated activity (Fig. 1B). Expression of PG alone resulted in an
intermediate activation presumably due to binding of PG to
endogenous transcription factors other than Lef-1, for instance
Tcf4 which is expressed in these cells and confers transcriptional
activation when transfected with PG [2,3]. Interestingly, when
the two consensus TBE [17,16] were deleted from the c-Myc pro-
moter (DTBE1/2, Fig. 1A and supplemental data 1), identical re-
sults as for the full-length promoter were obtained in wild-type
and b-catenin/ keratinocytes as well as primary human
keratinocytes (Fig. 1B, inset). Numerous repeats of these exper-
iments conﬁrmed that there was no diﬀerence in transcriptional
activity between the wild-type and the DTBE1/2 promoter in
either mouse keratinocytes or HK (Fig. 1B, inset).
3.2. Transcriptional regulation of the TBE1/2-deleted c-Myc
promoter is speciﬁcally mediated by PG and Lef-1
Wild-type keratinocytes were co-transfected with the wild-
type c-Myc promoter, DTBE1/2 and various plasmids encoding
truncated Lef-1 or PG. As it has been suggested that transcrip-
tional transactivation can be mistakenly attributed to PG due
to substitution by b-catenin [23], the reporter gene assays were
also repeated in b-catenin/ keratinocytes. The latter display
normal proliferation and onset of terminal diﬀerentiation [3].
For both, DTBE1/2 and the wild-type promoter constructs
PG-mediated suppression of transcription was dependent on
its direct interaction with Lef-1. This was demonstrated by
expression of a truncated form of Lef-1 (DLef-1) lacking the
armadillo binding domain [20]. When DLef-1 was co-expressed
with ectopic PG, PG was no longer able to repress Lef-1-med-
iated transcription (Fig. 1C, DLef-1). The ﬁnding that both
DLef-1 (data not shown) and Lef-1 were transcriptionally ac-
Fig. 1. Transcriptional regulation of the human c-Myc promoter by Lef-1 and PG in wildtype (WT), b-catenin/ (b-cat/) and PG/
keratinocytes. (A) Schematic representation of wild-type and TBE1/2 truncated c-Myc promoters used in the reporter gene assay. (B)–(D) WT and
(E)–(G) b-catenin/ keratinocytes were cotransfected with promoter constructs and plasmids encoding indicated human proteins. The vector
(Pc52) without insert was used as control. DLef-1 lacks the armadillo binding domain; PGDN, PGDC or PGArm plasmids lack the N-, C-terminus or
both, respectively. Consistent with Lef-1-mediated transcriptional activation in absence of PG, transfection of DLef-1 alone induced transcription to
a similar extent than Lef-1 alone (data not shown). The assays were run in duplicates except (F) and done between two and ﬁve times. A
representative example is shown. Luciferase activity was normalized for transfection eﬃciency by measuring renilla activity and the ratio is presented.
Bars represent the range. (B) Inset, primary human keratinocytes (HK); bar patterns like in (B).
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dillo proteins, as described previously [24–26]. Furthermore,
coexpression of Lef-1 with PG lacking the C-terminal domain
(Fig. 1D, PGDC; harbors the transactivation site [27]), abro-
gated PG-dependent suppression as did the deletion of boththe C- and the N-terminus (Fig. 1D, PGArm). When the PG
plasmid encoding a deletion of the N-terminus alone (PGDN;
shown to lack transactivating elements [27]) was co-expressed
with Lef-1, the same suppressive eﬀect was obtained as with
the wild-type PG.
Fig. 2. (A)–(C) Lef-1 and PG-mediated transcriptional regulation of engineered human c-Myc promoters containing deletions and point mutations
in TBE3 and TBE4 were assayed in wild-type (WT) keratinocytes. The assays were run in duplicates and done two times. Results were similar when
constructs were tested in b-catenin/ keratinocytes (data not shown). A representative example is shown. Bars represent the range; (A) *P < 0.05.
(B) *P < 0.05; n.s. = no signiﬁcant diﬀerence in two diﬀerent experiments. Bars represent the range.
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catenin/ keratinocytes gave similar results than wild-type
cells (Fig. 1F and data not shown). Together these results dem-
onstrate that PG and Lef-1-mediated transcription from the
DTBE1/2 and the wild-type c-Myc promoter is speciﬁc.
3.3. PG requires the consensus TBE for full promoter activation
in PG/ keratinocytes
Comparable to pre-neoplastic keratinocytes in the epidermis
[28], PG/ keratinocytes constitutively express c-Myc andhyperproliferate [2]. To address the usage of the consensus
TBE in these cells, Lef-1 and PG were co-expressed with the
wild-type and DTBE1/2 c-Myc promoter (Fig. 1G). Interest-
ingly, while PG repressed Lef-1-mediated transcription from
both promoters, transcriptional activation by ectopically ex-
pressed PG on its own was more eﬃcient from the wildtype
than the DTBE1/2 promoter, unlike in mouse wild-type and
b-catenin/ keratinocytes as well as primary human kerati-
nocytes (Fig. 1B, inset). Similar results were obtained with
transformed HaCat keratinocytes as well as HCT116 cells, a
C. Kolly et al. / FEBS Letters 581 (2007) 1969–1976 1973colon carcinoma cell line that constitutively actives c-Myc
transcription via Tcf4 [16,29] (data not shown). Together this
conﬁrms that in pre-neoplastic and neoplastic cells the consen-
sus TBE are indispensable for full promoter activity.
3.4. A new sequence variant of TBE is used by Lef-1 and PG to
suppress the c-Myc promoter in keratinocytes
Lack of diﬀerence between the wild-type and DTBE1/2 pro-
moter activity in keratinocytes raised the possibility that Lef-1
binds to other sites than the consensus TBE in the c-Myc
promoter. Keeping the core sequence –CAAAG– respectively
–CTTTG– of the consensus binding site 5 0-(A/T)(A/Relative intensity                                           2.3   6
TBE2 oligo 800            1      1     1            1      5    
TBE4 oligo 700            - - - - 1      
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Fig. 3. (A) Electrophoretic mobility shift assay showing binding of human re
ﬂuorescence; bottom panels: close ups of the same gel. The speciﬁcity of bind
TBE2 oligo (lane 2). Direct binding of Lef-1 to TBE2 and TBE4 but not to a m
keratinocytes between day 2 and day 4 after reaching conﬂuency (day 2, day 4
ampliﬁcation products obtained by real-time PCR following ChIP. Lower gra
were corrected for DNA input and normalized to the IgG control.T)CAAAG-3 0 [30] constant, we searched for TBE sequence
variants in the DTBE1/2 promoter. Three variants were identi-
ﬁed; the ﬁrst (5 0-CCCAAAG-3 0) (named TBE3) is present
270 bp upstream of the major transcription start site (P2),
and a second (5 0-CTTTGCC-3 0) and third (5 0-CTTTGCA-3 0)
(named TBE4) were found 185 bp and 210 bp, respectively,
downstream of this site.
To assess the importance of those sequence variants, we ﬁrst
introduced deletions comprising these sites and found up to
50% reduction in transcriptional activity (supplementary data
2). Repeats of these experiments in b-catenin/ keratinocytes
gave the same results (data not shown). To more speciﬁcally.8     1 6.5   1.8    2.9      
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post conﬂ.). The top panel schematically shows the localization of the
ph shows relative DNA amount obtained by real-time PCR. All values
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(MutTBE3) and TBE4+210 (MutTBE4) in the DTBE1/2 and
wild-type promoter (Fig. 2A). Mutation of TBE3 reduced
transcriptional activation by Lef-1 slightly but not signiﬁcantly
in both promoters. This demonstrated that TBE3 on its own is
not responsible for the Lef-1-mediated transcription of the
DTBE1/2 promoter construct we observed (Fig. 1). In contrast,
while no signiﬁcant reduction in transcriptional activity
occurred when TBE4+210 was mutated in the wild-type
promoter, its mutation in DTBE1/2 (DTBE1/2/MutTBE4)
decreased promoter activity by 50%. This demonstrated that
TBE4 is essential for mediating Lef-1 dependent transcription
in DTBE1/2, and suggested that TBE1 and TBE2 with TBE3
domains can substitute for mutation of TBE4. Simultaneous
mutation of TBE3 and TBE4 in DTBE1/2 (DTBE1/2/Mut-
TBE3/4) gave similar results as mutation of TBE4 alone
(DTBE1/2/MutTBE4). This is consistent with the above ﬁnding
that the TBE3 site on its own is not of major importance. In
addition, the fact that deletion of domains containing
TBE4+185 and TBE+210 in the DTBE1/2 promoter (supple-
mentary data 2) and mutation of TBE4+210 in DTBE1/2
(Fig. 2A) showed similar activity, suggested that TBE4+185
is not used, at least not in presence of TBE4+210.
TBE4+185 was therefore not further investigated and
TBE4+210 will be addressed in the following as TBE4.
Mutation of TBE4 in the DTBE1/2 promoter reduced Lef-1-
mediated transcription by around 50% (Fig. 2A). This indicated
that the this promoter contained other indispensable sequences
for Lef-1 regulation. To deﬁne such sequences, we introduced
progressive 5 0 deletions in the DTBE1/2 and DTBE1/2/Mut-
TBE4 promoters (Fig. 2B). When MutTBE4 was deleted up to
2 bp in front of the TATA box or 44 bp upstream of P2
(Dﬁ 44/MutTBE4), the promoter activity dropped and was
only twofold higher than the empty vector (without transcrip-
tional initiation site). Deletion of the two transcriptional initia-
tion sites including TBE1 and TBE2 (D TBE1/2/3/
D132ﬁ +33) reduced the activity to background (Fig. 2C).
Together these results demonstrate that additional regulatory
elements are present proximally or at the transcriptional initia-
tion site between position 108 and position +33. The fact that
Dﬁ 108/MutTBE4 and Dﬁ 44/MutTBE4 displayed diﬀer-
ent transcriptional activity further suggested that TBE4 and
these elements do not cooperate to drive transcriptional activity.
Collectively these experiments demonstrate that a novel se-
quence variant is capable of mediating Lef-1-induced transcrip-
tion driven by the human c-Myc promoter in keratinocytes, and
that TBE1 and TBE2 are dispensable when TBE4 is present.
3.5. Lef-1 binds to TBE4 in vitro and in vivo
To assess whether Lef-1 can bind to the new sequence vari-
ant 5 0-CTTTGCA-3 0, we compared the aﬃnity of Lef-1 for
TBE4 and TBE2 oligonucleotides (oligos) using electropho-
retic mobility shift assay with puriﬁed recombinant human
Lef-1 protein. To discriminate between an eﬀect of the ﬂanking
sequences which may inﬂuence binding [2] and the TBE se-
quences, the ﬂanking sequences were kept constant for all oli-
gos (corresponding to those of TBE4, see Section 2). The
binding of Lef-1 to the consensus TBE2 oligo was out-com-
peted with a 200-fold excess of unlabeled TBE2 oligo demon-
strating speciﬁcity of binding (Fig. 3A, lanes 2 and 3). Lef-1
similarly bound to the oligo with the sequence of the new var-iant TBE4 (Fig. 3A, lanes 4–9). In a competition experiment
binding of Lef-1 to the TBE4 oligo diminished when the con-
centration of TBE2 oligo was increased in the binding reaction
(Fig. 3A, lane 4) and vice versa (Fig. 3A, lane 5). This demon-
strated speciﬁc binding with comparable aﬃnity of Lef-1 to
both sequences. When the TBE4 sequence was mutated, Lef-
1 protein failed to bind, if alone (Fig. 3A, lane 10) or in com-
petition with TBE4 (Fig. 3A, lanes 7 and 8). When the concen-
tration of the mutated oligo was ﬁve times higher (Fig. 3A,
lane 9) some binding was detected, however it was marginal
and did not out-compete speciﬁc Lef-1 binding to the TBE4
oligo.
Recruitment of Lef-1 to TBE4 in vivo was addressed by
ChIP using normal primary HK (Fig. 3B). In mouse keratino-
cytes, endogenous Lef-1 is recruited to the c-Myc promoter
around day 4 post conﬂuency [1,2]. Hence we compared bind-
ing of endogenous Lef-1 to TBE1, 2, and 4 at day 2 and day 4
after cells had reached conﬂuency and were switched to high
calcium-containing medium. Supporting the predominant
usage of TBE4 in human keratinocytes in vivo when c-Myc
has to be suppressed [7,31,32], Lef-1 antibodies precipitated
TBE4-containing DNA fragments at day 4 but not at day 2
and the relative amount of TBE4-containing fragments was
four times higher than that of TBE2-containing fragments at
day 4. Recovered TBE1 fragments and a negative control frag-
ment 1 kb upstream of TBE1 were not above background as
deﬁned by immunoprecipitation with control IgG. In conclu-
sion Lef-1 directly binds to the TBE4 sequence in vivo and
in vitro.4. Discussion
We identiﬁed a new TBE sequence variant which is used to
regulate c-Myc transcription in epidermal keratinocytes. The
sequence diﬀers from the consensus TBE in the second position
from the 5 0-end to become TGCAAAAG in contrast to T(A/
T)CAAAAG [6–8]. In the presence of this sequence variant,
called here TBE4, the previously identiﬁed TBE1 and TBE2
are dispensable for both, PG or Lef-1-mediated activation
and Lef-1/PG-mediated repression of the human c-Myc pro-
moter in reporter gene assays. Similar results were obtained
in vivo using ChIP. In analogy to our ﬁndings in mouse kerat-
inocytes [2], in vivo the TBE4 appeared however to be used
exclusively to confer transcriptional repression, as seen by
Lef-1 recruitment to the c-Myc promoter in postconﬂuent
(day 4) keratinocytes when c-Myc needs to be silenced [1]. In
support of this, the position of TBE4 distal to the major tran-
scriptional initiation site coincides with the position demon-
strated to confer Lef-1-mediated transcriptional repression in
the mouse matrix metalloproteise-7 promoter [10]. Transcrip-
tional repression by Lef-1 and PG from the distal TBE4 con-
trasts with transcriptional transactivation by PG and b-
catenin from the proximal TBE1 and TBE2 in human colorec-
tal cancer cell lines and neoplastic kidney cells which was sug-
gested to be mediated by Tcf4 [16,17]. Likewise, TBE1 and
TBE2 are preferentially used by PG to activate transcription
in the PG/ keratinocytes that resemble pre-neoplastic cells
[2]. Comparable results were obtained in HaCat as well as in
the colon carcinoma cell line HCT116 (data not shown). This
suggests that the decision to target TBE1/2 or TBE4 in vivo
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with the preferential use of TBE1/2, Tfc4 expression is upreg-
ulated in papillomas and squamous cell carcinomas of skin
[33].
It is noticeable that the same TBE variant we report for the
c-Myc promoter is also present proximal to the transcriptional
initiation site in the human cyclin D1 promoter (unpublished
observation). This may suggest that the cyclin D1 promoter
is subject to a similar negative regulation pattern than the
c-Myc promoter. Interestingly, no variant TBE was found in
vicinity of the transcriptional initiation site on both the mouse
c-Myc and mouse cyclin D1 promoter raising the possibility
that in addition to more numerous TBE in the human than
in the mouse c-Myc promoter, humans may also have devel-
oped a more complex transcriptional control in response to
Wnt signaling than rodents.
Deletion of the c-Myc promoter up to 108 bp upstream of
the major transcriptional initiation site did not reduce tran-
scription unless the variant TBE was mutated. In association
with a promoter deletion up to 44 bp in front of the initiation
site, respectively 2 bp upstream of the TATA box, this activity
decreased to almost basal level (empty vector). This suggested
the presence of a co-regulatory element between position 108
and position 44 in addition to the variant TBE. Amongst a
few others, this promoter domain contains two consecutive
E2F binding sites and a third one at position 34. These sites
were reported to be indispensable for transcriptional regula-
tion of c-Myc by the oncogene v-Abl [34] or by cyclin D1
[35]. We did however not ﬁnd any change in c-Myc promoter
activity upon co-transfecting plasmids encoding human E2F-1,
E2F-4 or E2F-5 (data not shown). Hence, under the conditions
used here, the E2F factors did not seem of importance in driv-
ing transcription from the c-Myc promoter together with Lef-
1. Another family of transcriptional activators with a binding
site upstream of the TATA box are Myb transcription factors.
B-Myb was described to active the c-Myc promoter in African
Green Monkey kidney cells (CV-1 [36]), and BMyb is down-
regulated at G1 arrest in TGFb1-treated mouse keratinocytes
[37]. It is therefore conceivable that B-Myb is involved in c-
Myc activation during keratinocyte proliferation while Lef-
1/PG suppresses c-Myc at onset of terminal diﬀerentiation. It
should however also be considered that the deletion reducing
transcription close to basal level (empty vector) reaches up
to 2 bp in front of the TATA box (position 44). It can not
be excluded that this deletion aﬀects the basic transcription
machinery by interfering with the proper functioning of the
TATA box. The TATA box is indispensable for transcrip-
tional initiation as it serves to assemble RNA polymerase II
and general transcription factors such as TFIIA and the
TATA-binding protein (TBP). The high mobility protein-1
(HMG-1), that contains a HMG domain as does Lef-1, binds
to the TBP to form the HMG- 1/TBT/TATA complex [38]. It
was reported that UBF2, which also is a HMG box transcrip-
tion factor, directly associates with Lef-1 to potentate RNA
polymerase II-mediated transcription [27]. Also b-catenin
interacts with the TATA-binding protein in vitro [39]. Hence,
in addition to the TBE4, Lef-1 could also directly associate
with the basic transcription machinery. These collective possi-
bilities require more ample investigations.
The discovery of a new TBE variant described here provides
novel insights into c-Myc transcriptional repression by Lef-1/PG in non-neoplastic keratinocytes. In light of the important
role c-Myc and also cyclinD1 have in cancer, and their projected
therapeutic inhibition by b-catenin/TCF/Lef-1 interferingmole-
cules, additional binding sites and the necessary negative regula-
tion by Lef-1/PG required to suppress these genes under normal
conditions might have important implications.
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